Cowen says Alkermes (ALKS +2.4%) should be bought at current levels , citing the value of its...

|About: Alkermes plc (ALKS)|By:, SA News Editor

Cowen says Alkermes (ALKS +2.4%) should be bought at current levels , citing the value of its diabetes drug Bydureon and its potential profitability for the company. The firm believes the royalty stream could be worth more than $1B, or $8 per share, which would drive significantly higher valuations.